Current Issue

Featured article

The case against rituximab maintenance

Bruce D. Cheson

The monoclonal antibody, rituximab, is used to treat lymphomas. This article discusses the results of randomized trials that suggest patients with follicular lymphoma should not receive rituximab maintenance therapy.

Current Issue

Featured article

Refractory neuroendocrine tumor—response to liposomal doxorubicin and capecitabine

Masi et al.

This Case Study describes a patient with metastatic typical carcinoid of the lung who had not responded to initial therapy with a somatostatin analog and chemotherapy (cisplatin and etoposide). She achieved an impressive and long-lasting response to the combination of capecitabine and lyposomal doxorubicin, without reporting any severe adverse effects. The authors discuss the diagnosis, examine differential diagnosis and briefly review the available treatment options in this setting.

Current Issue

Also in this issue

• News and Views: Follicular lymphoma: maintenance therapy is (often) indicated

• Review: Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics

• Review: New advances that enable identification of glioblastoma recurrence

Society News

ESO

The European School of Oncology (ESO) in partnership with Nature Reviews Clinical Oncology is pleased to announce the 76th e-grandround, entitled "Breast cancer heredity (in co-operation with OECI)". This topic will be discussed by Dr. Stefania Tommasi, during a live webcast on Thursday 26 November 17:15–18:00 UK time. Online participants will be able to submit questions.

Please visit www.e-eso.net for further information.